Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pfizer Inc 66 HUDSON BOULEVARD EAST NEW YORK NY 10001 USA

www.pfizer.com Employees: 81,000 P: 212-733-2323

Sector:

Medical

Description:

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.'The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Key Statistics

Overview:

Market Capitalization, $K 130,024,328
Enterprise Value, $K 193,332,320
Shares Outstanding, K 5,685,366
Annual Sales, $ 63,627 M
Annual Net Income, $ 8,031 M
Last Quarter Sales, $ 13,715 M
Last Quarter Net Income, $ 2,967 M
EBIT, $ 17,236 M
EBITDA, $ 24,249 M
60-Month Beta 0.58
% of Insider Shareholders 0.06%
% of Institutional Shareholders 68.36%
Float, K 5,681,955
% Float 99.94%
Short Volume Ratio 0.43

Growth:

1-Year Return -22.41%
3-Year Return -58.03%
5-Year Return -41.28%
5-Year Revenue Growth 22.95%
5-Year Earnings Growth 5.42%
5-Year Dividend Growth 16.67%

Per-Share Information:

Most Recent Earnings 0.92 on 04/29/25
Next Earnings Date N/A
Earnings Per Share ttm 3.21
EPS Growth vs. Prev Qtr 46.03%
EPS Growth vs. Prev Year 12.20%
Annual Dividend Rate, $ 1.70
Annual Dividend Yield 7.43%
Most Recent Dividend 0.430 on 05/09/25
Next Ex-Dividends Date 05/09/25
Dividend Payable Date 06/13/25
Dividend Payout Ratio 52.40%
Most Recent Split 3-1 on 07/01/99

PFE Ratios

Ratio
Price/Earnings ttm 7.19
Price/Earnings forward 7.49
Price/Earnings to Growth 0.83
Return-on-Equity % 20.33%
Return-on-Assets % 8.53%
Profit Margin % 12.62%
Debt/Equity 0.69
Price/Sales 2.06
Price/Cash Flow 5.29
Price/Book 1.44
Book Value/Share 15.98
Interest Coverage -1.47

PFE Dividends

Date Value
05/09/25 $0.4300
01/24/25 $0.4300
11/08/24 $0.4200
07/26/24 $0.4200
05/09/24 $0.4200
01/25/24 $0.4200
11/09/23 $0.4100
07/27/23 $0.4100
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar